Disc Medicine Bitopertin Receives FDA Complete Response Letter for Erythropoietic Protoporphyria
Disc Medicine, Inc. (NASDAQ: IRON) disclosed on February 13, 2026, that the U.S. Food and Drug Administration issued a Complete Response Letter for the New Drug Application for bitopertin, an oral glycine transporter 1 inhibitor under development as a treatment for erythropoietic protoporphyria. The company's announcement stated that the bitopertin NDA had been under review for accelerated approval and as part of the Commissioner's National Priority Voucher pilot program. The FDA's decision means the application cannot be approved in its current form, and additional data will be required before the agency can reconsider the submission.
FDA's Rationale: Surrogate Endpoint Association Not Demonstrated
The Complete Response Letter centered on the evidentiary standard required for accelerated approval, which depends on two conditions: evidence of an effect on a proposed surrogate endpoint, and whether that surrogate is reasonably likely to predict clinical benefit. The FDA agreed that data from the Phase 2 AURORA and BEACON trials provided sufficient evidence that bitopertin significantly lowers whole blood metal-free protoporphyrin IX, the biomarker proposed as a surrogate endpoint. However, the agency concluded that those same trials did not demonstrate an association between the percent change in PPIX and sunlight exposure-based clinical endpoints as measured in the studies. The FDA acknowledged what it described as strong mechanistic and biological plausibility supporting the use of PPIX as a biomarker in protoporphyria but determined that this plausibility alone was insufficient to support accelerated approval without evidence linking the biomarker change to clinical outcomes.
The FDA indicated that results from the ongoing Phase 3 APOLLO study could serve as evidence to support traditional approval, effectively redirecting the regulatory pathway from accelerated to traditional and requiring completion of the confirmatory trial before a resubmission can proceed.
Disc Medicine Bitopertin: Mechanism and Clinical Context
Bitopertin is a small-molecule, orally administered inhibitor of glycine transporter 1, a membrane transporter expressed on developing red blood cells. GlyT1 is required to supply glycine for heme biosynthesis and to support erythropoiesis. By inhibiting this transporter, bitopertin is designed to reduce the availability of glycine as a substrate for heme production, thereby decreasing the synthesis of protoporphyrin IX at its source. This mechanism represents a disease-modifying approach to erythropoietic protoporphyria treatment, as it targets the underlying pathophysiology of PPIX overproduction rather than managing symptoms downstream.
EPP is a rare inherited metabolic disorder caused by deficiency in the enzyme ferrochelatase, the final enzyme in the heme biosynthesis pathway. The resulting accumulation of PPIX in red blood cells and skin causes severe phototoxic reactions upon exposure to visible light. Patients experience episodes of intense burning pain that can persist for hours to days, often with minimal visible skin changes, a feature that has historically contributed to diagnostic delays and underrecognition. The disease typically manifests in early childhood and imposes lifelong restrictions on outdoor activity, education, employment, and social participation. A subset of patients develops protoporphyric hepatopathy, which can progress to liver failure requiring transplantation.
From Roche to Disc Medicine: The Program's Lineage
Bitopertin was originally discovered and developed by F. Hoffmann-La Roche for central nervous system indications, principally schizophrenia. Roche advanced the compound through multiple Phase 3 trials under the SearchLyte program, which did not meet primary endpoints. Roche subsequently deprioritized the asset. Disc Medicine obtained global rights to bitopertin under a license agreement from Roche in May 2021 and repurposed the molecule for hematologic diseases, applying the same GlyT1 inhibition mechanism to a different therapeutic rationale: modulating heme biosynthesis in erythroid precursors rather than synaptic glycine levels in the brain. Disc Medicine is the sole entity responsible for the current development program and regulatory strategy.
Regulatory History and the Path to the FDA Complete Response Letter for Bitopertin
This is the first Complete Response Letter issued for bitopertin in the EPP indication. The NDA submission was based on data from the Phase 2 AURORA trial, a double-blind, placebo-controlled study, and the Phase 2 open-label BEACON trial, supplemented by data from the HELIOS open-label extension study. The application sought accelerated approval on the basis of PPIX reduction as a surrogate endpoint reasonably likely to predict clinical benefit. No prior advisory committee meeting for bitopertin in EPP has been publicly reported. Bitopertin is not approved for use in any jurisdiction worldwide for any indication.